CDKN2A

CDKN2A is a tumor suppressor gene that produces proteins (p16/INK4a and p14/ARF) which help control cell division and prevent damaged cells from becoming cancerous. When CDKN2A is deleted or inactivated, cells can grow uncontrollably. Loss of CDKN2A is one of the most common genetic changes found in mesothelioma tumors.

Origin

The gene was identified in the early 1990s and named for its function: Cyclin-Dependent Kinase Inhibitor 2A. Its frequent deletion in mesothelioma was documented in the late 1990s, and it has since become a cornerstone marker in modern mesothelioma pathology.

Significance in Asbestos Context

For patients undergoing workup for suspected mesothelioma, CDKN2A testing, usually performed by a FISH (fluorescence in situ hybridization) test looking for deletion of the p16 locus, is one of the most important tools pathologists use to distinguish malignant mesothelioma from benign reactive changes in the pleura or peritoneum. Benign reactive cells generally retain CDKN2A, while mesothelioma cells typically show homozygous (both copies) deletion. A confirmed CDKN2A deletion on biopsy can clarify a diagnosis that is otherwise ambiguous on standard staining, and it may also carry prognostic information, as homozygous deletion has been associated with more aggressive disease in some studies. In a legal claim, the genetic and pathology findings, including CDKN2A status, appear in the medical records that document the mesothelioma diagnosis and help establish that the disease is malignant rather than a benign asbestos-related condition.

Example Sentence

The pathology report noted homozygous deletion of CDKN2A by FISH, which the oncologist explained was a key piece of evidence confirming the pleural biopsy showed mesothelioma rather than reactive scarring.

Related Terms

BAP1, FISH (Fluorescence In Situ Hybridization), Mesothelioma, Immunohistochemistry, MTAP, Tumor Suppressor Gene

Notes

• Ask your pathologist or oncologist whether CDKN2A FISH testing (or the related MTAP immunostain, which often substitutes as a surrogate marker) was performed on your biopsy. This is now standard practice in distinguishing mesothelioma from benign mesothelial proliferations.
• Request a copy of the full surgical pathology report, including any molecular and FISH results; these documents are important both for treatment decisions and for any legal claim.
• If your initial biopsy was read as "atypical mesothelial proliferation" or "cannot rule out mesothelioma," ask whether CDKN2A testing could help resolve the diagnosis before pursuing more invasive procedures.
• CDKN2A status may be relevant when discussing clinical trial eligibility, as some experimental therapies target pathways downstream of this gene loss.